Related Experiment Videos
Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46)
M Manchester1, A Valsamakis, R Kaufman
1Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037.
Abstract:
The human complement regulatory protein membrane cofactor protein (CD46) is the cellular receptor for measles virus (MV), whereas decay accelerating factor (DAF; CD55), a structurally similar complement regulatory protein, does not bind MV. To characterize the interaction between MV and CD46, mutants of the CD46 protein and hybrid molecules between CD46 and DAF were tested for their ability to act as MV receptors. The transmembrane domain and cytoplasmic tail of CD46 were not required for receptor function as cells expressing the CD46 extracellular domain linked to the glycosyl-phosphatidylinositol tail of DAF were rendered susceptible to MV infection. Chimeric proteins exchanging the four extracellular short consensus repeat (SCR) domains between CD46 and DAF indicated that only molecules with both SCR1 and SCR2 from CD46 allowed a productive MV infection. Further, monoclonal antibodies (mAbs) against SCR1 or SCR2 of CD46 blocked MV infection, whereas a mAb against SCR3 and SCR4 did not. The latter mAb blocks C3b/C4b binding (which maps to SCR3 and SCR4) whereas the former mAbs do not. Thus, our data indicate that both SCR1 and SCR2 make up the MV receptor determinant in CD46. These results also suggest avenues for development of therapeutic agents to inhibit MV binding and thus infection and disease.
Insights
Membrane cofactor protein (CD46) binds measles virus (MV) via its SCR1 and SCR2 domains, not the transmembrane or cytoplasmic regions. This finding identifies key viral binding sites on CD46 for potential therapeutic development.
Area of Science:
- Virology
- Immunology
- Cell Biology
Background:
- Membrane cofactor protein (CD46) is the cellular receptor for measles virus (MV).
- Decay accelerating factor (DAF; CD55), a similar protein, does not bind MV.
- Understanding the MV-CD46 interaction is crucial for antiviral strategies.
Purpose of the Study:
- To pinpoint the specific domains of CD46 responsible for MV binding.
- To investigate the role of different CD46 structural regions in MV receptor function.
- To identify potential targets for inhibiting MV infection.
Main Methods:
- Constructing CD46 mutants and CD46-DAF chimeric proteins.
- Testing the susceptibility of engineered cells to MV infection.
- Utilizing monoclonal antibodies (mAbs) against CD46 domains to block MV binding.
Main Results:
- The extracellular domain of CD46, specifically SCR1 and SCR2, is essential for MV binding.
- The transmembrane domain and cytoplasmic tail of CD46 are not required for MV receptor function.
- Monoclonal antibodies targeting SCR1 or SCR2 blocked MV infection, while those targeting SCR3/SCR4 did not.
Conclusions:
- The MV receptor determinant on CD46 resides within the SCR1 and SCR2 domains.
- These findings provide a basis for developing therapeutics to inhibit MV binding and infection.
- Targeting CD46's SCR1 and SCR2 domains offers a promising strategy against measles virus.